Data reveals deals from every airport in the US to save members money on their next flight
Portland, Oregon, Nov. 16, 2021 (GLOBE NEWSWIRE) — Scott’s Cheap Flights, a service that tracks airfare prices and alerts its 2+ million members to exceptional airfare deals, released data from all of the deals they sent from every airport in the US to find out which destinations are the cheapest to get to from each state. Whether you have a bucket list destination in mind or simply want to snag the cheapest flight to your continent of choice, these are the cheapest fares to destinations outside of the 50 states Scott's Cheap Flights found from across the US.
Some examples include:
– The cheapest city to fly to from New York, New Jersey, Connecticut, Oklahoma, Colorado, Washington, Tennessee, Montana, New Mexico, and California is San Juan, Puerto Rico.
– The cheapest European city to fly to from Arizona and Nebraska is Helsinki, Finland, while the cheapest to fly from Illinois is Reykjavik, Iceland.
– The cheapest Asian city to fly to from Texas and Louisiana is Tokyo, Japan, while the cheapest to fly from Nevada and Georgia is Hong Kong.
About Scott’s Cheap Flights
Since 2015, Scott’s Cheap Flights has helped members around the world make their travel dreams come true. We combine sophisticated software and human Flight Experts to discover flight deals and mistake fares up to 90% off and email them to our 2+ million members. Unlike fully automated fare alerts services, every deal alert we send to members has passed a rigorous quality evaluation by our team to ensure it's worth members’ hard-earned money and limited travel time. Our members save an average of $200 on domestic economy flights, $550 on international economy flights, and $2,000 on international business and first-class flights. Every month we receive over 1,000 testimonials from happy members who’ve scored a great deal on a flight thanks to our email.
Attachments
Mapping the Cheapest Places to Fly From Each State
Mapping the Cheapest Places to Fly From Each State
Stock picker and hedge manager Cathie Wood made some serious waves last year, when her ARK Innovation ETF outperformed the S&P 500 by an order of magnitude. From the pandemic trough in March to the end of 2020, the S&P gained 68%, while Wood’s flagship fund surged ahead by 153%. It was an astounding performance. Wood made smart choices last year, targeting tech companies, remote connections, and telehealth for investment. All of those segments saw big gains in business during the lockdown phases
Buffett turned millions into billions without EV darlings in the U.S. Here's how.
(Bloomberg) — Investor sentiment sagged Monday amid turmoil for President Joe Biden’s economic agenda and rising global omicron infections, spurring selloffs in stocks, equity futures and oil, while bolstering sovereign bonds.Most Read from BloombergSouth Africa Hospitalization Rate Plunges in Omicron WaveBiden to Issue ‘Stark Warning’ on Vaccination Amid Covid SurgeStocks, Futures Sink on Manchin Shock, Virus: Markets WrapEurope Braces for More Covid Lockdowns as U.K. Cases SurgeModerna’s Thir
Here are three growth stocks that will skyrocket 50% or more in 2022, according to Wall Street. The consensus 12-month price target for Sea Limited (NYSE: SE) reflects an upside potential of 89%. Sea's past success has been primarily driven by its Free Fire mobile game.
COPENHAGEN (Reuters) -Novo Nordisk shares fell as much as 16% on Monday after the Danish drugmaker was hit by U.S. supply issues for its new obesity drug as it seeks to establish a market foothold before the launch of a rival drug by Eli Lilly. The obesity market has proved difficult for pharmaceuticals companies, but Novo made a breakthrough with its Wegovy drug. In a stock announcement after Friday's market close, Novo said that a contract manufacturer filling syringes for pens to inject the drug had halted deliveries and manufacturing temporarily after issues relating to good manufacturing practice.
There are plenty of options when it comes to vaccine stock investing these days. Adria Cimino (Ocugen): Ocugen surged more than 700% in a matter of weeks earlier this year on optimism about potential coronavirus vaccine sales. The biotech company partnered with Bharat Biotech to co-commercialize that company's vaccine — Covaxin — in the U.S. The deal later expanded to include Canada.
While there's no way to know for sure if a given stock has what it takes to outperform, looking at a company's upcoming catalysts is one trick that can help to stack the deck in your favor. Catalyst Pharmaceuticals (NASDAQ: CPRX) makes a drug called Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Since the drug's first sales in 2019, the company's quarterly revenue has exploded by a shocking 7,090%.
If you haven't heard about the saver's credit, you may be leaving cash on the table.
It isn't a stretch to argue that the world literally can't live without the steady innovation taking place throughout the healthcare industry. The world is aging, and more people are being diagnosed with chronic conditions such as diabetes and heart disease. This is exactly why the Organisation for Economic Cooperation and Development (OECD) anticipates that healthcare spending as a proportion of GDP in developed nations will grow from an average of 8.8% in 2018 to 10.2% by 2030.
FEATURES – MAIN The U.S. stock market hasn’t followed the script in 2021. The index returned 26% through Dec. 16, well ahead of the roughly 10% gain projected, on average, by strategists at the start of the year.
(Bloomberg) — Just as investors were wrapping up this year’s trading, the threat of new lockdowns sent shock waves through markets across the world. Most Read from BloombergSouth Africa Hospitalization Rate Plunges in Omicron WaveBiden to Issue ‘Stark Warning’ on Vaccination Amid Covid SurgeStocks, Futures Sink on Manchin Shock, Virus: Markets WrapEurope Braces for More Covid Lockdowns as U.K. Cases SurgeModerna’s Third Dose Boosts Antibodies Against OmicronSentiment in stocks and bonds remaine
Many names throughout the NASDAQ are down 30%, 50%, 75% from their highs. Meanwhile, consumer electronics giant Apple (NASDAQ: AAPL) is near 52-week highs and up 40% over the past twelve months, a sign that investors are selling smaller, riskier stocks and buying large and established stocks like Apple. Here is why Apple could be the biggest disappointment of 2022.
Futures tumbled, threatening a market rally that's been chopping up investors financially and mentally, Omicron fears are growing and lockdowns returning.
The global tally for the coronavirus-borne illness climbed above 274.7 million on Monday, while the death toll edged above 5.35 million, according to
The Omicron variant may be starting to weigh on economic activity. Here's top news and what to watch in the markets on Monday, December 20, 2021.
In this article, we discuss the 10 electric car stocks to buy for 2022. If you want to skip our detailed analysis of these stocks, go directly to the 5 Electric Car Stocks to Buy for 2022. In 2021, electric vehicle sales surged in China and Europe, with the countries reporting 1.2 million and 1.4 […]
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility…
At first glance, Alibaba Group Holdings might seem like a tempting deal. Alibaba, and other Chinese businesses, continue to face uncertainty around stock delistings, geopolitical tensions and China’s regulatory crackdowns. As Barron’s previously reported, some money managers have recently started buying shares of Alibaba.
In this article, we discuss the 10 best dividend stocks to buy according to Joel Greenblatt’s Gotham Asset Management. You can skip our detailed analysis of Greenblatt’s hedge fund and its returns over the years, and go directly to read 5 Dividend Stocks to Buy According to Joel Greenblatt’s Gotham Asset Management. Joel Greenblatt is […]
The Cambridge drugmaker said on Monday that lab tests show its booster shot of the Covid-19 vaccine increases neutralizing antibody levels against omicron approximately 37-fold compared to pre-boost levels.